US FDA approves Sanofi’s Enjaymo for cold agglutinin disease treatment
Enjaymo is intended to reduce the need for red blood cell transfusion caused due to hemolysis in CAD patients. The drug is a humanised monoclonal antibody that selectively
Diamyd Medical has announced the receipt of fast track designation from the US Food and Drug Administration (FDA) for type 1 diabetes treatment, Diamyd.